{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:40:25Z","timestamp":1787017225864,"version":"build-2736575974"},"reference-count":52,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T00:00:00Z","timestamp":1770940800000},"content-version":"unspecified","delay-in-days":12,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Lupus Sci Med"],"accepted":{"date-parts":[[2026,1,16]]},"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Although treatment guidelines recommend pulse steroids, induction treatment of lupus nephritis (LN) varies significantly among providers. This paper aims to explore evidence that intravenous pulse provides pharmacological benefits along with improved clinical efficacy without greater toxicity compared with high-dose oral glucocorticoids justifying inclusion for all active LN.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a systematic literature review (SLR) using the term \u2018pulse glucocorticoids in LN\u2019 in order to identify studies that summarise the pharmacologic mechanisms of glucocorticoids, reviewed the historical use of glucocorticoids in SLE, and compared pulse therapy with high-dose oral treatment related to their efficacy and toxicities.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>SLR demonstrated that non-genomic mechanisms of action are more associated with pulse than oral steroids. Some observational studies reported improved renal responses with pulse steroids but in exchange for more adverse metabolic bone disease effects (eg, osteoporosis and avascular necrosis) as well as infections and, importantly, mortality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Current guidelines promoting pulse therapy for all forms of proliferative LN (and in the case of American College of Rheumatology 2024 treatment guidelines, even isolated class V membranous LN) rely on structured evidence grading processes, including expert consensus and observational data, but are not based on head-to-head randomised controlled trial comparisons. Therefore, there can be an ongoing debate regarding the best approach. The SLR identifies a distinct pharmacological benefit unique to pulse treatment, though without direct evidence necessary for the treatment of LN; includes observational studies with evidence of superior efficacy, but not consistently; and identifies a higher risk of adverse effects. In our opinion, the data advocates for a more selective approach to treatment, foregoing universal treatment with pulse steroids, based on a toxicity versus benefit assessment that patients with mild disease do not require the additional risks.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/lupus-2025-001748","type":"journal-article","created":{"date-parts":[[2026,2,15]],"date-time":"2026-02-15T19:25:14Z","timestamp":1771183514000},"page":"e001748","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Induction treatment of lupus nephritis: to pulse or not to pulse? Whether \u2019tis nobler to universally or selectively prescribe"],"prefix":"10.1136","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8493-7658","authenticated-orcid":false,"given":"Emily","family":"Gutowski","sequence":"first","affiliation":[{"name":"Rheumatology, NYU Grossman School of Medicine, New York City, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3389-2976","authenticated-orcid":false,"given":"Howard Michael","family":"Belmont","sequence":"additional","affiliation":[{"name":"Rheumatology, NYU Langone Health, New York City, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,2,15]]},"reference":[{"key":"2026021511250517000_13.1.e001748.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2023.09.002"},{"key":"2026021511250517000_13.1.e001748.2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.62.6.556"},{"key":"2026021511250517000_13.1.e001748.3","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1002\/acr.21664","article-title":"American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis","volume":"64","author":"Hahn","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2026021511250517000_13.1.e001748.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2017.11.023"},{"key":"2026021511250517000_13.1.e001748.5","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.200161"},{"key":"2026021511250517000_13.1.e001748.6","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1093\/rheumatology\/keae041","article-title":"A path to Glucocorticoid Stewardship: a critical review of clinical recommendations for the treatment of systemic lupus erythematosus","volume":"63","author":"Bertsias","year":"2024","journal-title":"Rheumatology (Oxford)"},{"key":"2026021511250517000_13.1.e001748.7","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200544010-00003"},{"key":"2026021511250517000_13.1.e001748.8","first-page":"S13","article-title":"Pharmacodynamics of glucocorticoids","volume":"29","author":"Strehl","year":"2011","journal-title":"Clin Exp Rheumatol"},{"key":"2026021511250517000_13.1.e001748.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2005.11.012"},{"key":"2026021511250517000_13.1.e001748.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2018.11.002"},{"key":"2026021511250517000_13.1.e001748.11","doi-asserted-by":"publisher","DOI":"10.1002\/art.20583"},{"key":"2026021511250517000_13.1.e001748.12","first-page":"1265","article-title":"Glucocorticoid dose dependent downregulation of glucocorticoid receptors in patients with rheumatic diseases","volume":"27","author":"Sanden","year":"2000","journal-title":"J Rheumatol"},{"key":"2026021511250517000_13.1.e001748.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2006.08.027"},{"key":"2026021511250517000_13.1.e001748.14","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.01823","article-title":"Implicating the Role of GILZ in Glucocorticoid Modulation of T-Cell Activation","volume":"10","author":"Cannarile","year":"2019","journal-title":"Front Immunol"},{"key":"2026021511250517000_13.1.e001748.15","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2019.00308","article-title":"Glucocorticoid-Induced Leucine Zipper: A Novel Anti-inflammatory Molecule","volume":"10","author":"Bereshchenko","year":"2019","journal-title":"Front Pharmacol"},{"key":"2026021511250517000_13.1.e001748.16","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1952.02930280017006"},{"key":"2026021511250517000_13.1.e001748.17","first-page":"495","article-title":"Effect of large doses of prednisone on the renal lesions and life span of patients with lupus glomerulonephritis","volume":"57","author":"Pollak","year":"1961","journal-title":"J Lab Clin Med"},{"key":"2026021511250517000_13.1.e001748.18","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1542\/peds.40.5.822","article-title":"Treatment of systemic lupus erythematosus complicated by nephritis in children","volume":"40","author":"Hagge","year":"1967","journal-title":"Pediatrics"},{"key":"2026021511250517000_13.1.e001748.19","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(76)91272-1"},{"key":"2026021511250517000_13.1.e001748.20","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S0307-742X(21)00212-5","article-title":"Pulse methylprednisolone in SLE","volume":"8","author":"Kimberly","year":"1982","journal-title":"Clin Rheum Dis"},{"key":"2026021511250517000_13.1.e001748.21","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(81)90538-6"},{"key":"2026021511250517000_13.1.e001748.22","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(82)80203-5"},{"key":"2026021511250517000_13.1.e001748.23","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-125-7-199610010-00003"},{"key":"2026021511250517000_13.1.e001748.24","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-135-4-200108210-00009"},{"key":"2026021511250517000_13.1.e001748.25","doi-asserted-by":"publisher","DOI":"10.1002\/art.43212"},{"key":"2026021511250517000_13.1.e001748.26","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2025-001562","article-title":"Long-term efficacy and safety of the Lupus-Cruces Nephritis protocol: a propensity score study of the Lupus-Cruces and Lupus-Bordeaux cohorts","volume":"12","author":"Ruiz-Irastorza","year":"2025","journal-title":"Lupus Sci Med"},{"key":"2026021511250517000_13.1.e001748.27","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2019.102359","article-title":"Prolonged remission in SLE is possible by using reduced doses of prednisone: An observational study from the Lupus-Cruces and Lupus-Bordeaux inception cohorts","volume":"18","author":"Ruiz-Irastorza","year":"2019","journal-title":"Autoimmun Rev"},{"key":"2026021511250517000_13.1.e001748.28","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s11926-023-01109-6","article-title":"Flares in Lupus Nephritis: Risk Factors and Strategies for Their Prevention","volume":"25","author":"Banos","year":"2023","journal-title":"Curr Rheumatol Rep"},{"key":"2026021511250517000_13.1.e001748.29","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224762"},{"key":"2026021511250517000_13.1.e001748.30","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.1093\/rheumatology\/keae547","article-title":"A retrospective evaluation of glucagon-like peptide-1 receptor agonists in systemic lupus erythematosus patients","volume":"64","author":"Carlucci","year":"2025","journal-title":"Rheumatology (Oxford)"},{"key":"2026021511250517000_13.1.e001748.31","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2013.10.013"},{"key":"2026021511250517000_13.1.e001748.32","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2017.05.017"},{"key":"2026021511250517000_13.1.e001748.33","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2021.102898","article-title":"Eurolupus cyclophosphamide plus repeated pulses of methyl-prednisolone for the induction therapy of class III, IV and V lupus nephritis","volume":"20","author":"Ruiz-Irastorza","year":"2021","journal-title":"Autoimmun Rev"},{"key":"2026021511250517000_13.1.e001748.34","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1002\/art.42920","article-title":"Impact of Glucocorticoid Dose on Complete Response, Serious Infections, and Mortality During the Initial Therapy of Lupus Nephritis: A Systematic Review and Meta\u2010Analysis of the Control Arms of Randomized Controlled Trials","volume":"76","author":"Figueroa\u2010Parra","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"2026021511250517000_13.1.e001748.35","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1093\/ndt\/gfae294","article-title":"Optimal glucocorticoid therapy in lupus nephritis","volume":"40","author":"Figueroa-Parra","year":"2025","journal-title":"Nephrol Dial Transplant"},{"key":"2026021511250517000_13.1.e001748.36","unstructured":"Furie RA , Houssiau FA , Lightstone L , et al . Belimumab Improves Renal Responses in Patients with or Without Steroid Pulses During Induction Therapy for Lupus Nephritis [abstract]. Arthritis Rheumatol 2021;73 (suppl 9)."},{"key":"2026021511250517000_13.1.e001748.37","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2024-001351","article-title":"Low versus high initial oral glucocorticoid dose for lupus nephritis: a pooled analysis of randomised controlled clinical trials","volume":"12","author":"Saxena","year":"2025","journal-title":"Lupus Sci Med"},{"key":"2026021511250517000_13.1.e001748.38","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.semarthrit.2019.11.006","article-title":"The safety of pulse corticosteroid therapy- Systematic review and meta-analysis","volume":"50","author":"Edel","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"2026021511250517000_13.1.e001748.39","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1177\/09612033251369050","article-title":"Avascular necrosis in patients with systemic lupus erythematosus: Prevalence, associations, risk factors and outcome","volume":"34","author":"\u00c7etin","year":"2025","journal-title":"Lupus"},{"key":"2026021511250517000_13.1.e001748.40","doi-asserted-by":"crossref","first-page":"148","DOI":"10.5152\/eurjrheum.2023.23068","article-title":"Infections in Patients with Systemic Lupus Erythematosus: The Contribution of Primary Immune Defects Versus Treatment-Induced Immunosuppression","volume":"10","author":"Kunzler","year":"2023","journal-title":"Eur J Rheumatol"},{"key":"2026021511250517000_13.1.e001748.41","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keu148"},{"key":"2026021511250517000_13.1.e001748.42","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2021-000590","article-title":"Impact of glucocorticoids on the incidence of lupus-related major organ damage: a systematic literature review and meta-regression analysis of longitudinal observational studies","volume":"8","author":"Ugarte-Gil","year":"2021","journal-title":"Lupus Sci Med"},{"key":"2026021511250517000_13.1.e001748.43","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200008)43:8<1801::AID-ANR16>3.0.CO;2-O"},{"key":"2026021511250517000_13.1.e001748.44","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1002\/acr.23322","article-title":"Restrictive Use of Oral Glucocorticoids in Systemic Lupus Erythematosus and Prevention of Damage Without Worsening Long\u2010Term Disease Control: An Observational Study","volume":"70","author":"Ruiz\u2010Arruza","year":"2018","journal-title":"Arthritis Care Research"},{"key":"2026021511250517000_13.1.e001748.45","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780401119"},{"key":"2026021511250517000_13.1.e001748.46","doi-asserted-by":"publisher","DOI":"10.1016\/j.arth.2015.03.036"},{"key":"2026021511250517000_13.1.e001748.47","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.170837"},{"key":"2026021511250517000_13.1.e001748.48","doi-asserted-by":"publisher","DOI":"10.1191\/0961203302lu243oa"},{"key":"2026021511250517000_13.1.e001748.49","doi-asserted-by":"crossref","first-page":"587","DOI":"10.7326\/0003-4819-91-4-587","article-title":"NIH conference. Systemic lupus erythematosus: evolving concepts","volume":"91","author":"Decker","year":"1979","journal-title":"Ann Intern Med"},{"key":"2026021511250517000_13.1.e001748.50","doi-asserted-by":"publisher","DOI":"10.34067\/KID.0005512021"},{"key":"2026021511250517000_13.1.e001748.51","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1002\/acr.20441","article-title":"Predicting outcomes of lupus nephritis with tubulointerstitial inflammation and scarring","volume":"63","author":"Hsieh","year":"2011","journal-title":"Arthritis Care Research"},{"key":"2026021511250517000_13.1.e001748.52","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043731"}],"container-title":["Lupus Science &amp; Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/lupus-2025-001748","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,15]],"date-time":"2026-02-15T19:25:17Z","timestamp":1771183517000},"score":1,"resource":{"primary":{"URL":"https:\/\/lupus.bmj.com\/lookup\/doi\/10.1136\/lupus-2025-001748"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,2,15]]},"published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10.1136\/lupus-2025-001748"],"URL":"https:\/\/doi.org\/10.1136\/lupus-2025-001748","relation":{},"ISSN":["2053-8790"],"issn-type":[{"value":"2053-8790","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2]]}}}